Immune Camouflaging in Tumors: Implications for Neoantigen Vaccines

Time: 11:00 am
day: Day Two


  • JanusMatrix™, integrated in the Ancer® neoantigen discovery platform, is a specialized in silico tool used to distinguish effector from inhibitory neoantigens
  • Ancer® analysis of tumors derived from nivolumab-treated melanoma patients reveals patterns consistent with immune camouflaging: lowered immunogenicity and increased tolerogenic signals
  • Relevant neoantigen targets may be harder to identify once patients are treated with checkpoint inhibitors. Neoantigen vaccines may be better administered prior to checkpoint inhibitor therapy